How much cash does Tyra Biosciences, Inc. generate?

Tyra Biosciences, Inc. (TYRA) generated -$102.3M in operating cash flow over the trailing twelve months.

What is Tyra Biosciences, Inc.'s free cash flow?

After $215.0K of capital expenditures, Tyra Biosciences, Inc.'s free cash flow was -$102.5M over the trailing twelve months, down 39.0% year over year.

Where does Tyra Biosciences, Inc.'s cash flow data come from?

Every line is extracted from Tyra Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Tyra Biosciences, Inc. TYRA Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$131.11M-9.3%	-$119.95M-7.4%	-$111.68M-5.5%	-$105.83M-9.7%	-$96.44M-11.5%
Depreciation and amortization	$541K-0.9%	$546K-2.2%	$558K+0.7%	$554K+2.6%	$540K+4.0%
Stock-based compensation	$29.43M+5.1%	$28.01M+3.4%	$27.08M0.0%	$27.08M+7.8%	$25.11M+10.1%
Change in accounts payable	$4.93M+46.3%	$3.37M—	——	——	——
Net cash from operating activities	-$102.26M-7.5%	-$95.14M-4.4%	-$91.11M-5.2%	-$86.63M-18.3%	-$73.2M-4.9%
Capital expenditures	$215K+52.5%	$141K+56.7%	$90K-12.6%	$103K-81.0%	$542K-18.4%
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of common stock	——	——	——	——	——
Net cash from financing activities	$166.3M+1,953%	$8.1M+96.5%	$4.12M-2.3%	$4.22M+5.2%	$4.01M-98.0%
Net increase (decrease) in cash	——	——	——	——	——
Prepaid expenses and other current assets	$5.26M-4.2%	$5.48M-25.9%	$7.4M-1.7%	$7.52M+169%	$2.79M+1,553%
Increase Decrease In Right Of Use Assets And Lease Liabilities Net	$78K-6.0%	$83K-6.7%	$89K-8.2%	$97K-4.0%	$101K-45.1%
Proceeds From Issuance Of Common Stock Under Benefit Plans	$18.44M+128%	$8.1M+96.5%	$4.12M-2.3%	$4.22M-1.0%	$4.26M+66.6%
Accrued payables for capital expenditures	$88K+29.4%	$68K+172%	$25K+174%	-$34K-278%	-$9K—
Receivable From Exercise Of Stock Options Included In Prepaid Expenses And Other Current Assets	——	$241K+33.3%	$180.75K+50.0%	$120.5K+100%	$60.25K—
Vesting Of Options Early Exercised Subject To Repurchase	——	——	——	——	$29K-32.6%
Free cash flow	-$102.47M-7.5%	-$95.28M-4.5%	-$91.2M-5.2%	-$86.73M-17.6%	-$73.75M-4.7%
Free cash flow	-$102.47M-7.5%	-$95.28M-4.5%	-$91.2M-5.2%	-$86.73M-17.6%	-$73.75M-4.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Tyra Biosciences, Inc. generate?: Tyra Biosciences, Inc. (TYRA) generated -$102.3M in operating cash flow over the trailing twelve months.
What is Tyra Biosciences, Inc.'s free cash flow?: After $215.0K of capital expenditures, Tyra Biosciences, Inc.'s free cash flow was -$102.5M over the trailing twelve months, down 39.0% year over year.
Where does Tyra Biosciences, Inc.'s cash flow data come from?: Every line is extracted from Tyra Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.